Tenon Medical, Inc. 8-K

What Happened Tenon Medical, Inc. (TNON) announced on its March 17, 2026 Form 8‑K that on March 11, 2026 it entered into securities purchase agreements to issue an aggregate $4.3 million of 20% Original Issue Discount (OID) Senior Convertible Promissory Notes in a private placement. The company issued a press release on March 12, 2026 announcing the closing.

Key Details

• Aggregate principal issued: $4.3 million of 20% OID senior convertible promissory notes.
• Maturity: September 11, 2026 (company may extend to December 11, 2026); if extended, outstanding principal increases by 5%.
• Conversion: Notes are convertible after six months into common stock at a conversion price equal to 80% of the Volume-Weighted Average Price (VWAP) for the three trading days prior to conversion (i.e., a 20% discount), subject to adjustments.
• Prepayment & financing terms: voluntary prepayments are payable at 102.5% of principal; the company must prepay an amount equal to 15% of net proceeds from any future securities financing.
• Placement agent: WallachBeth Capital LLC; fee = 7.0% of gross proceeds plus $65,000 expense reimbursement.
• Offering: Private placement exempt from registration under Section 4(a)(2) and/or Regulation D.

Why It Matters This financing provides Tenon with near-term cash (approximately $4.3M gross) but comes with short maturity and features that can affect shareholders. The convertible feature (conversion at a 20% discount after six months) can dilute existing equity if converted. The 20% OID and placement fees reduce net proceeds, and the short maturity (roughly six months unless extended) means the company may need additional financing or to refinance these notes quickly. Investors should note the potential for dilution and the company’s reliance on short-term capital raised via a private placement.